NCT02405221View on ClinicalTrials.gov

Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

April 4, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

January 31, 2025

Conditions
HPV16 Associated Cervical Cancer
Interventions
BIOLOGICAL

TA-CIN (arm)

TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.

BIOLOGICAL

TA-CIN (thigh)

TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.

Trial Locations (2)

21287

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

35233

Women & Infants Center, University of Alabama at Birmingham, Birmingham

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

PapiVax Biotech, Inc.

OTHER

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT02405221 - Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer | Biotech Hunter | Biotech Hunter